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Abstract
Background: Acute behavioural disturbance (ABD) is an increasing problem in emergency departments. This study 
aimed to determine the impact of a structured intramuscular (IM) sedation protocol on the duration of ABD in the 
emergency department.
Methods: A historical control study was undertaken comparing 58 patients who required physical restraint and 
parenteral sedation with the structured IM sedation protocol, to 73 historical controls treated predominantly by 
intravenous sedation, according to individual clinician preference. The primary outcome was the duration of the ABD 
defined as the time security staff were required. Secondary outcomes were the requirement for additional sedation, 
drug related-adverse effects and patient and staff injuries.
Results: The median duration of the ABD in patients with the new sedation protocol was 21 minutes (IQR: 15 to 35 
minutes; Range: 5 to 78 minutes) compared to a median duration of 30 minutes (IQR: 15 to 50 minutes; Range: 5 to 135 
minutes) in the historical controls which was significantly different (p = 0.03). With IM sedation only 27 of 58 patients 
(47%; 95% CI: 34% to 60%) required further sedation compared to 64 of 73 historical controls (88%; 95%CI: 77% to 94%). 
There were six (10%) drug-related adverse events with the new IM protocol [oxygen desaturation (5), oxygen 
desaturation/airway obstruction (1)] compared to 10 (14%) in the historical controls [oxygen desaturation (5), 
hypoventilation (4) and aspiration (1)]. Injuries to staff occurred with three patients using the new sedation protocol 
and in seven of the historical controls. Two patients were injured during the new protocol and two of the historical 
controls.
Conclusion: The use of a standardised IM sedation protocol was simple, more effective and as safe for management of 
ABD compared to predominantly intravenous sedation.
Background
Acute behavioural disturbance (ABD) is a regular occur-
rence in emergency departments (ED) and is one of the
commonest indications for sedation to be utilised in the
ED[1]. There are numerous causes of ABD in the ED, but
drug and alcohol intoxication or withdrawal, confusion
and agitation related to behavioural disorders or threat-
ening self harm or poisoning, are the most frequent[2,3].
The optimal goal in the management of patients with
ABD is to ensure safety for the patient, staff and other
patients.
Considerable literature focuses on the sedation of
patients in psychiatric institutions[4-7] where most
patients have psychotic illness, and the requirement for
rapid sedation is less common. Despite the existence of
numerous guidelines for sedation of aggressive patients in
the ED[8,9], there are limited studies on this[3,10-15],
predominantly focusing on comparing different drug
types. There are few studies specifically examining struc-
tured approaches to sedating agitated patients[2] and no
studies comparing different routes of administration of
sedation in the ED. Currently numerous different seda-
tive drugs and combinations of drugs are used, given var-
iously by the intramuscular (IM) and the intravenous (IV)
route. The lack of evidence often results in treatment
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choices being determined by individual staff preference
resulting in little consistency in the management of these
difficult patients.
As part of a clinical trial to compare different drugs for
IM sedation in the ED, a structured approach to sedation
was introduced which involved IM sedation only being
used as the initial route of sedation. The same ED had
previously used predominately IV sedation in this patient
group[2]. This study aimed to investigate the impact of
this structured approach for sedation on duration of ABD
episodes, requirements for additional sedation and the
effect on drug related adverse events.
Methods
Setting and study design
We undertook a historical control study to investigate the
effect of the introduction of a standardised protocol for
the sedation of violent behaviour in the ED that exclu-
sively used the IM route of administration for sedation.
Patients treated using the new IM sedation protocol were
compared to historical controls. The historical controls
were taken from the period prior when the existing prac-
tice was to predominantly use IV sedation. The struc-
tured IM sedation protocol was introduced as part of a
clinical trial comparing droperidol (10 mg), midazolam
(10 mg) and a combination of droperidol (5 mg) and
midazolam (5 mg). The clinical trial is described in detail
elsewhere. Ethics approval was obtained for the historical
control study from the Human Research Ethics Commit-
tee.
The hospital where the study was undertaken has a ter-
tiary toxicology unit, and although there are only 27,000
presentation to the ED annually, there is a high propor-
tion of patients with agitation, delirium, aggression and
acute behavioural disorders because the hospital provides
a regional clinical toxicology service and Drug and Alco-
hol Unit[2].
Selection of Participants
The study compared patients treated with the new struc-
tured IM sedation protocol during an eight month period
from August 2008 to March 2009 to a group of historical
control patients sedated in the ED in the eight month
period immediately before the protocol was introduced
(November 2007 to June 2008). The structured IM seda-
tion protocol consisted of:
1.An intramuscular injection of the clinical trial drug, 
which was labelled and kept in the ED.
2.A defined approach to monitoring of the patient's 
vital signs over a six hour period
3.The introduction and use of a sedation score to be 
included as part of the standard observation of the 
patient
4.Recording of further sedation, adverse events, staff 
or patient injury for all patients.
5.Route and type of additional sedation was dictated 
by the treating clinician.
Inclusion criteria for both the historical controls (use of
predominantly IV parenteral sedation) and the interven-
tion group (IM sedation only) were that the patient
required both physical and chemical restraint, the patient
did not consent to IV or oral sedation and they required
the presence of the hospital security. To identify and
ensure that the historical control group was similar to
patients during the new IM sedation protocol we
accessed the hospital security log for both time periods.
The security log documents all security responses to
ABD in the ED and has previously been shown to be the
most accurate record of patients with ABD[2]. Medical
records were retrieved for all patients who had required
security to attend the ED and only patients meeting the
inclusion criteria were included. Exclusion criteria were
successful verbal de-escalation, agreement to oral or IV
sedation, previous administration of other sedative medi-
cation or the patient did not remain in the ED (escorted
off premises by police, absconded) (Figure 1).
Data Collection and Processing
Data was recorded prospectively as part of the new struc-
tured sedation protocol on standardised datasheets
which were then entered into a relational database. The
duration of the ABD was taken from the security log. All
outcomes were defined prior to the introduction of the
sedation protocol. Identical data items were extracted
retrospectively from the medical records of patients in
the historical control group. The extraction process was
undertaken by one investigator (LAC) but was reviewed
by a second investigator (GKI) for the first ten patients.
There were no differences in the recording of the out-
comes between the two investigators.
The following data were included for the study analysis:
patient demographic characteristics (age, sex), cause of
ABD, duration of the ABD episode, any use of additional
sedation in the patient including the time of administra-
tion, drug related adverse effects and injuries to patients
and staff.
Methods of Measurement
Information was recorded by an investigator or research
nurse for a six hour period after initial sedation. For his-
torical controls the medical record was used to obtain
information from the standard ED observation chart. For
all patients including historical controls, the duration of
the ABD was extracted from the security log based on the
time from the initial call time to security to the "all clear"
time when they are released from attendance. The secu-
rity staff defined an "all clear" when the patient is safelyCalver et al. BMC Emergency Medicine 2010, 10:14
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secured by all four limbs, a mask is in situ if the patient is
spitting, the patient is sedated or settling and the verbal
abuse is abating or ceased. This is determined in consul-
tation with the clinical staff present at the time. The secu-
rity staff and ED clinical staff were not aware that the
duration of ABD was the primary outcome for the study.
During the new sedation protocol, additional medica-
tions used and adverse events were recorded prospec-
tively and checked with the patient's medication chart
and medical record. For historical controls this informa-
tion was extracted from the medication chart and medi-
cal record. The data for the historical controls and
patients in the intervention period were the same because
it is mandatory routine patient documentation.
Main Interventions
The intervention was the introduction of a structured IM
sedation protocol for ABD patients in the ED that
involved initial sedation via the IM route with pre-deter-
mined medications [droperidol (10 mg), midazolam (10
mg) or a combination of droperidol (5 mg) and midazo-
lam (5 mg)]. Prior to the study the use of sedation, includ-
ing the drug type used and the route of administration
was dictated by either the treating ED doctor or the con-
sultant emergency physician or clinical toxicologist
responsible for the patient. However, the vast majority of
sedation used was administered via the IV route, rather
than the IM route, and a selection of either benzodiaz-
epines, antipsychotics or a combination of both were
used in varying doses in each patient[2]. Recruitment to
Figure 1 Flow chart illustrating all patients with a ABD recorded in the security log and which were during the new protocol or included in 
the historical control group.
Historical 
Controls
112
73 historical controls 
Sedated and restrained 
39 Excluded 
Verbal de-escalation (19) 
Agreed to oral or IV (0) 
Age (1) 
Transferred (1) 
No physical restraint (8) 
Absconded (2) 
Escorted off premises (2) 
No chemical sedation (6) 
Psychosis (0) 
New Protocol 
136
72 Excluded 
Verbal de-escalation (33) 
Agreed to oral or IV (5) 
Age (1) 
Transferred (2) 
No physical restraint (21) 
Absconded (2) 
Escorted off premises (2) 
No chemical sedation (4) 
Psychosis (2) 
Not recruited (missed) 
6
58 patients with the new protocol 
Sedated and restrained Calver et al. BMC Emergency Medicine 2010, 10:14
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the prospective study was assisted by in-servicing which
helped to ensured that all of the patients who required
parenteral sedation and mechanical restraint were
recruited to the study due to staff awareness and only six
were missed (Figure 1).
Main Outcomes
The primary outcome was the duration in minutes of the
ABD comparing patients during the new intervention to
the historical controls. Other outcomes included the
requirement for additional sedation and adverse effects
from the sedative medication, which includes both
patient and staff incidents. Additional sedation included
further sedation required to obtain initial sedation as well
as re-sedation if the patient re-emerged still agitated. Re-
sedation was defined as sedation after an interval exceed-
ing one hour where no further sedation was given during
that time, based on repeat sedation in a previous study[2].
Sedative related adverse effects included any episodes of
oxygen desaturation (< 90%), hypoventilation (respiratory
rate < 12), requirement for airway intervention or sup-
port, arrhythmias or hypotension. Staff or patient injuries
were also determined for both groups and were reported
during both periods as per hospital guidelines for inci-
dent monitoring.
Data Analysis
Medians and interquartile ranges (IQR) are reported for
all continuous variables. Percentages are reported for
dichotomous outcomes with 95% confidence intervals
(CI). Comparison of continuous variables between the
two groups was performed using the non-parametric
Mann-Whitney test. Statistical analysis was performed
using Prism 5.01 (GraphPad Software Inc).
Results
There were 58 patients recruited during 8 month period
where the new IM sedation protocol was used. These
were compared to 73 historical control patients that simi-
larly required parenteral sedation in the 8 month period
prior to the new IM protocol. Only 20 of the 73 historical
controls (27%) initially received IM sedation, compared
to all patients for the IM sedation protocol. Baseline char-
acteristics for both groups are compared in Table 1 and
are similar except for the larger proportion of males dur-
ing the new protocol.
The median duration of the ABD in patients with the
new sedation protocol was 21 minutes (IQR: 15 to 35
minutes; Range: 5 to 78 minutes) compared to a median
duration of 30 minutes (IQR: 15 to 50 minutes; Range: 5
to 135 minutes) in the historical controls which was sig-
nificantly different (p = 0.03) [Figure 2].
With the new IM sedation protocol 27 of the 58
patients (47%; 95%CI: 34% to 60%) required further seda-
tive medication at any time compared to 64 of the 73 his-
torical control patients (88%; 95%CI: 77% to 94%). The
increased number of historical controls requiring further
sedation was both for failed sedation in the initial period;
and for re-sedation, as follows: 14 of 58 patients (24%;
95% CI: 14% to 37%) required further additional sedation
compared to 47 of 73 historical controls (64%; 95% CI:
52% to 75%). The number of patients that required re-
sedation with the new IM sedation protocol was 18 of 58
patients (31%; 95% CI: 20% to 45%) compared to 36 of 73
historical control patients (49%; 95% CI: 38% to 61%).
Of the 36 historical control patients re-sedated, 27 were
re-sedated once, five re-sedated twice, two re-sedated
three times and two re-sedated four times. In compari-
son, of the 18 patients with the new IM sedation protocol
re-sedated, eleven were re-sedated once, three re-sedated
twice, three re-sedated three times and one re-sedated six
times. Figure 3 provides the total number of sedative drug
administrations for both groups of patients. There were
six (10%; 95% CI: 4% to 21%) sedative drug-related
adverse events with the new IM protocol [oxygen desatu-
ration (4), oxygen desaturation/airway obstruction (1),
oxygen desaturation and atrial fibrillation (1)] compared
to 10 (14%; 95% CI: 7% to 24%) in the historical controls
[oxygen desaturation (5), hypoventilation (4) and aspira-
tion (1)]. Injuries to staff occurred with three patients
using the new sedation protocol and in seven cases with
the historical controls. There were two patients injured
during the new IM sedation protocol and two of the his-
torical controls.
Discussion
The study shows that a structured approach to sedation
of ABD by using the IM route resulted in a reduced dura-
tion of ABD and less additional medication for sedation
in the initial and subsequent episodes, compared to exist-
ing practice with predominantly IV sedation. In addition
this was achieved without an increase in adverse events.
This approach using the IM route has clear advantages
because it means that sedation can be initiated rapidly in
these dangerous patients who require mechanical
restraint without gaining IV access. This will potentially
reduce the risk of injury to staff and patients.
The reduced duration of the ABD, regardless of which
drug was administered, is predominantly due to the fact
that a structured IM protocol meant that the dose and
route were established and treatment could be initiated
immediately, often at the nursing staff's suggestion. In
addition, IM sedation can be given rapidly without the
need to gain IV access. The reduced time may therefore
be a product of the practicalities of rapidly administering
sedative medication - no need for IV access, rapid deci-
sion making and mechanical restraint - rather than the
pharmacokinetics of the route of administration.Calver et al. BMC Emergency Medicine 2010, 10:14
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There is the need for a clear distinction between the
duration of the ABD as opposed to the time to sedation.
The ABD duration is measured from when the security
staff are called to the ED. This can often include the time
from when the patient is still ambulant or when the
patient arrives in the ambulance or with police escort,
until the "all clear" when security is no longer required.
The time to sedation is the time it takes to achieve effec-
tive sedation from the time of drug administration and is
usually measured using some form of sedation score. The
fact that the IM route reduces the duration of the ABD is
more likely due to shortening the time until administra-
tion rather than the time from administration to sedation.
In this study the time to sedation could not be deter-
mined for the historical control group because sedation
scores were only introduced as part of the new protocol.
Similar numbers of sedative related adverse effects with
the new IM sedation protocol compared to historical
controls was important because one of the concerns
about using IM sedation is the risk of over-sedation. One
study comparing IM ziprasidone, droperidol and midazo-
lam reported respiratory depression in 15% of patients[3],
similar to our study. Another study of high dose midazo-
lam in acutely agitated ED patients, where two thirds
received it via the IM route, reported adverse events in
eight of 61 patients (13%)[16]. The drug was not known
for each patient in our study and may differ between
those receiving droperidol, midazolam or both.
There were limitations to the study because of the use
of historical controls. Every attempt was made to ensure
the two groups were similar (Figure 2, Table 2). However,
the fact that sedative medications were not given in a
standard way in the historical control group meant that
the proportion who received benzodiazepines, antipsy-
chotics and medication by the intramuscular route dif-
fered between the controls and the intervention group
(Table 1). Potentially the success of the standardised
intramuscular sedation protocol may have been because
more patients received droperidol. This may explain the
reduced requirement for additional sedation in the inter-
vention group[3,14]. However, it is unlikely that more
patients receiving droperidol in the intervention group
accounts for the shortened duration of ABD because dro-
peridol does not have a more rapid onset of action than
benzodiazepines[10].
There were differences in the source of the data
between the historical controls and the interventional
Table 1: Baseline characteristics of the historical control patients compared to patients with the new protocol of 
intramuscular sedation
Historical Controls
(N = 73)
New Protocol
(N = 58)
Age (median, IQR) 30 years
(23 to 38 years)
32 years
(26 to 43 years)
Sex (male) 35 (48%) 32 (60%)
Initial intramuscular sedation* 20 (27%) 58 (100%)
Benzodiazepines 63 (86%) 67%†
IQR - interquartile range; ABD - acute behavioural disturbance; *The remainder received IV sedation (53). †Exact number unknown but based 
on randomisation approximately one third received 10mg midazolam and one third 5mg midazolam and one third only droperidol.
Figure 2 Box and whisker plots showing the duration of the ABD 
comparing historical control patients to patients with the new se-
dation protocol. The whiskers are the 5th and 95th percentiles, the box 
the interquartile range, extreme outliers are filled circles and the medi-
an by the full line across the box.
Figure 3 Box and whiskers plot showing the number of total drug 
administration, including the initial sedation, comparing histori-
cal control patients to patients with the new sedation protocol. 
The whiskers are the 5th and 95th percentiles, the box the interquartile 
range, extreme outliers are filled circles and the median by the full line 
across the box.Calver et al. BMC Emergency Medicine 2010, 10:14
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group. However, the main outcomes in the study were
determined prior to the new protocol being introduced
and the retrospective data extraction for the historical
controls. The duration of ABD was taken from the secu-
rity log for both the historical controls and patients dur-
ing the intervention period. The security staff were
unaware that these times were used as the primary out-
come for the study and there is no reason believe that the
times were recorded differently in each period. The reli-
ability of the recording of drug related adverse effects in
the historical controls was dependent upon the accuracy
of documentation by the clinical staff in the medical
record. Therefore, there is a likelihood that some patients
with or without adverse effects were missed in the histor-
ical controls. This would only underestimate the adverse
effects in the historical controls because adverse events
were prospectively monitored with the new sedation pro-
tocol and recorded on the data sheets. Information
recorded regarding additional sedation is likely to be
accurate for the historical controls because sedative med-
ication is unlikely to be given without a written order.
There is a reasonable possibility that the reduction in
ABD time and decreased need for additional sedation
was in part due to research being undertaken with a study
n u r s e  b e i n g  a v a i l a b l e  t o  a s s i s t  w i t h  d a t a  c o l l e c t i o n  2 4
hours a day - the Hawthorne effect. Even so, this is not
necessarily a limitation and demonstrates that a struc-
tured approach to ABD with additional staffing provides
improved sedation and treatment of these patients. How-
ever, the on-call staff members took approximately 20 to
30 minutes to arrive in the ED to assist with the data col-
lection and in most cases the ABD was controlled and the
security all clear called prior to their arrival.
Titrated intravenous sedation may have in fact been the
intention in some historical control patients and there-
fore not considered a negative outcome. However, the
time taken to give further sedation requires additional
clinical time as it necessitates the presence of a medical
officer and further ongoing 5 minutely observations by
nursing staff. The patient's distress and struggle also con-
tinue to be prolonged in the case of repeated sedation
attempts which are not in the patient's best interest. This
delay in achieving sedation exposes the already chaotic
ED to further disruption and increases risk of staff injury.
It is difficult to determine if the difference in the dura-
tion of ABD of 9 minutes is clinically significant and no
previous studies have defined this. However, many would
consider even 5 minutes in which a patient remains vio-
lent and aggressive and requiring security staff as being
important. More importantly, the study shows that an IM
sedation protocol is not inferior to a previously predomi-
nantly IV sedation and that such an approach is a feasible
and safe alternative.
This study has potential relevance to regional hospitals
which do not have the luxury of multiple security guards
or even sufficient staff to adequately contain many of
these patients. In this setting, an IM sedation protocol
that does not require initial IV access, that acts reason-
ably rapidly and is safe, would be highly beneficial. With
appropriate studies, such an approach may also be
extended to other settings, such as psychiatric hospitals
or the pre-hospital setting[11,13].
However, it may not be possible to immediately genera-
lise these results to some other settings, based on the
population of patients studied. The cause of ABD will dif-
fer with some hospitals having larger numbers of recre-
ational overdoses, including amphetamine toxicity[14],
compared to the predominant population of patients with
deliberate self-harm and alcohol intoxication in our
study[2]. It will be important to confirm this work to
include other groups of patients because there is no rea-
son that IM sedation should not be just as effective based
o n  t h e  f a c t  t h a t  i t  a p p e a r s  t o  b e  t h e  p r a c t i c a l i t i e s  o f
Table 2: Reasons for acute behavioural disturbance (ABD) in the historical controls and patients with the new protocol
Reason for ABD Historical Controls New Protocol
Alcohol intoxication 31 (42%) 14 (24%)
Deliberate self-harm 21 (28%) 20 (34%)
Deliberate self-harm and alcohol
intoxication
9 (12%) 12 (21%)
Drug induced delirium/agitation* 9 (12%) 9 (15%)
Psychosis 0 2 (3%)
Personality disorder 0 1 (2%)
Drug withdrawal 0 0
Other (medical) 3 (4%)† 0
* including amphetamines, olanzapine; † urinary tract infection, head injury and hepatic encephalopathyCalver et al. BMC Emergency Medicine 2010, 10:14
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administration rather than the drug type or administra-
tion route pharmacokinetics.
Further investigation is required to determine the best
approach to the patient who fails initial sedation and/or
requires several re-sedation episodes. The major problem
with these patients is whether it is appropriate to repeat
IM sedation, and if this will result in over-sedation.
Because these patients remain violent and dangerous and
it may still be difficult to obtain IV access, further IM
sedation would be preferable if it can be shown to be safe
and effective.
Conclusion
We have shown that a structured approach to sedating
agitated patients in the ED, where all initial doses of seda-
tion were given IM, was simple, more effective and as safe
for the management of ABD compared to the prior prac-
tice of using predominantly IV sedation. The duration of
the ABD was shortened, less medication was used for
additional sedation, and there were no increase in seda-
tive related adverse events. The benefits of using the IM
route in the ED may be translated to other settings with
patients with ABD given the advantage of increased
safety and effectiveness.
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